NCT00048308

Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 3,000 (planned)
• Sponsor: Alexion Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

During a heart bypass procedure, a substance called "complement" is released by the body. This complement causes inflammation, which can lead to side effects such as chest pain, heart attacks, heart failure, or impairment of memory, language and motor skills. The purpose of this study is to find out if the study drug (pexelizumab), which blocks complement release, can reduce such side effects and be taken safely.

Conditions

• Cardio-pulmonary Bypass
• Coronary Artery Bypass Graft

Interventions

Type	Name	Description
DRUG	pexelizumab

Timeline

• Start date: 2002-01-01
• Primary completion: 2003-03-01
• First posted: 2002-10-31
• Last updated: 2017-02-23

Locations

186 sites across 2 countries: United States, Canada